Riluzole

Generic Name: Riluzole

Brand Names: Exservan, Rilutek, Tiglutik, Riluzole Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₈H_₅F_₃N_₂OS

CAS Number: 1744-22-5

Unique Ingredient Identifier: 7LJ087RS6F

Background: A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.

Indication: For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)

Associated Conditions: Amyotrophic Lateral Sclerosis (ALS)

Associated Therapies: -

Clinical Trials

Impact of Persistent Conductances on Motor Unit Firing in SCI

Not Applicable

Conditions: Chronic Spinal Cord Injury

Interventions: Drug: Memantine
Procedure: Therapeutic muscle stretching
Drug: sugar pill
Drug: Riluzole
Drug: Isradipine

First Posted Date: 2014-05-13

Last Posted Date: 2014-05-13

Lead Sponsor: Shirley Ryan AbilityLab

Target Recruit Count: 50

Registration Number: NCT02136823

Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders

Early Phase 1

Completed

Conditions: Autism Spectrum Disorders

Interventions: Other: placebo
Drug: Riluzole

First Posted Date: 2014-03-07

Last Posted Date: 2021-01-14

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 8

Registration Number: NCT02081027

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)

Phase 1

Completed

Conditions: PTSD

Interventions: Drug: Riluzole

First Posted Date: 2013-12-24

Last Posted Date: 2020-04-01

Lead Sponsor: Yale University

Target Recruit Count: 18

Registration Number: NCT02019940

Locations: 🇺🇸
Clinical Neuroscience Division, National Center for PTSD, West Haven, Connecticut, United States

MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial

Phase 2

Completed

Conditions: Secondary Progressive Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Riluzole
Drug: Amiloride
Drug: Fluoxetine

First Posted Date: 2013-07-29

Last Posted Date: 2020-03-26

Lead Sponsor: University College, London

Target Recruit Count: 445

Registration Number: NCT01910259

Locations: 🇬🇧
Gartnavel Royal Hospital, 1055 Great Western Road, Glasgow, United Kingdom
🇬🇧
The Walton Centre, Liverpool, United Kingdom
🇬🇧
Derriford Hospital, Plymouth, United Kingdom

and more 10 locations

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Other: Placebo tablets
Drug: CK-2017357
Drug: Riluzole

First Posted Date: 2012-10-18

Last Posted Date: 2020-03-31

Lead Sponsor: Cytokinetics

Target Recruit Count: 711

Registration Number: NCT01709149

Locations: 🇺🇸
Texas Neurology, Dallas, Texas, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Drexel Neurology, Philadelphia, Pennsylvania, United States

and more 72 locations

Riluzole Augmentation Pilot in Depression (RAPID) Trial

Phase 2

Terminated

Conditions: Major Depressive Disorder

Interventions: Drug: Riluzole
Drug: Sertraline
Other: placebo

First Posted Date: 2012-10-10

Last Posted Date: 2019-08-28

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 21

Registration Number: NCT01703039

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Riluzole in Mild Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: Riluzole

First Posted Date: 2012-10-10

Last Posted Date: 2021-09-22

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 50

Registration Number: NCT01703117

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD

Phase 2

Completed

Conditions: Autism Spectrum Disorders

Interventions: Drug: Placebo
Drug: Riluzole

First Posted Date: 2012-08-10

Last Posted Date: 2017-03-20

Lead Sponsor: Evdokia Anagnostou

Target Recruit Count: 58

Registration Number: NCT01661855

Locations: 🇨🇦
Lawson Health Research Institute, London, Ontario, Canada
🇨🇦
Offord Centre for Child Studies, Hamilton, Ontario, Canada
🇨🇦
Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada

Riluzole in Spinal Cord Injury Study

Phase 2

Terminated

Conditions: Spinal Cord Injury

Interventions: Drug: Placebo
Drug: Riluzole

First Posted Date: 2012-05-14

Last Posted Date: 2021-04-19

Lead Sponsor: AOSpine North America Research Network

Target Recruit Count: 193

Registration Number: NCT01597518

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Wisconsin - Madison, Madison, Wisconsin, United States
🇺🇸
University of Missouri, Columbia, Missouri, United States

and more 26 locations

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Recurrent Melanoma
Refractory Malignant Solid Neoplasm
Stage III Cutaneous Melanoma AJCC v7
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Riluzole
Drug: Sorafenib Tosylate

First Posted Date: 2011-02-24

Last Posted Date: 2024-07-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT01303341

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy